Central and Mucosal Immunities are Modified by Non Adsorbable Antibiotic Treatment in Uncomplicated Diverticular Disease

F Pandolfi; S Frosali; L Petruzziello; E E Newton; G Costamagna

doi:10.2174/1389557515666150722104035

Central and Mucosal Immunities are Modified by Non Adsorbable Antibiotic Treatment in Uncomplicated Diverticular Disease

Mini Rev Med Chem. 2015;16(3):218-21. doi: 10.2174/1389557515666150722104035.

Authors

F Pandolfi, S Frosali, L Petruzziello, E E Newton, G Costamagna¹

Affiliation

¹ Institute of Internal Medicine, Catholic University of Rome, Italy. pandolfi@rm.uni.catt.it.

PMID: 26202195
DOI: 10.2174/1389557515666150722104035

Abstract

We review our experience on Rifaximin in uncomplicated diverticular disease. Our data show that a 2 week treatment induces modifications in the immune system: local mucosal lymphocytes with TLR-4 were increased. In the peripheral blood CD103 cells, which increased before treatment, returned to normal values after Rifaximin.

Publication types

Review

MeSH terms

Diverticulitis, Colonic / drug therapy*
Gastrointestinal Absorption / drug effects
Gastrointestinal Microbiome / drug effects
Humans
Immunity / drug effects
Immunity, Mucosal / drug effects
Intestinal Mucosa / drug effects
Rifamycins / pharmacology
Rifamycins / therapeutic use*
Rifaximin

Substances

Rifamycins
Rifaximin